The International Journal of Biomaterials, published by HINDAWI LTD, is a premier platform for disseminating groundbreaking research in the fields of biomaterials and biomedical engineering. With an Open Access approach since 2009, this journal provides unhindered access to innovative studies and applications aimed at advancing medical technologies and improving patient outcomes. Notably ranked in the Q3 category for both Biomaterials and Biomedical Engineering in 2023, it serves as an essential resource for researchers, practitioners, and students alike. The journal's Scopus rankings, including a 49th percentile in Biomedical Engineering and a 40th percentile in Biomaterials, further underscore its growing prominence in the academic community. With contributions spanning from 2011 to 2024, the journal seeks to foster collaborative research and promote developments that enhance the understanding and application of biomaterials in healthcare.

Bioengineering & Translational Medicine, published by WILEY, positions itself at the forefront of innovation in the fields of biomedical engineering, biotechnology, and pharmaceutical science. With an impressive impact factor reflected through its top-tier Q1 rankings in multiple categories, the journal serves as a critical platform for disseminating cutting-edge research and stimulating discourse among professionals and scholars since its establishment as an open-access journal in 2016. Key to its mission is facilitating the translation of bioengineering research into tangible medical applications, thereby enhancing healthcare outcomes. With its comprehensive scope, it attracts a diverse readership, including researchers, industry leaders, and students eager to engage with the latest developments in translational medicine. The journal operates under robust access options, ensuring that research is freely available for maximum reach and impact, fostering collaboration and innovation across disciplines worldwide.

VIEW is a prestigious journal published by WILEY that focuses on the rapidly evolving fields of Biomaterials and Biomedical Engineering. Since its inception in 2020, VIEW has established itself as an open-access platform dedicated to disseminating high-quality research and innovation within these disciplines. With an impressive impact factor that places it in the Q1 category of both Biomaterials and Biomedical Engineering, VIEW ranks among the top journals in its field, boasting a 91st percentile ranking in Biomedical Engineering and an 85th percentile ranking in Materials Science. Researchers, professionals, and students are encouraged to utilize this invaluable resource, as it provides a comprehensive view of current advancements and future trends in biomaterial science and engineering. Positioned in the United Kingdom, VIEW operates as a vital scholarly communication link, fostering collaboration and knowledge sharing within an ever-growing global community.

Biomaterials Research, published by the American Association for the Advancement of Science, is a prominent open access journal established in 2014, dedicated to advancing the field of biomaterials. Based in the United Kingdom, this journal has swiftly become an essential platform for researchers and practitioners, offering groundbreaking insights in biomaterials, biomedical engineering, ceramics and composites, and miscellaneous medical fields. With its impressive Q1 ranking across multiple relevant categories in 2023 and its strong Scopus rankings, including a remarkable 90th percentile in the medicine category, Biomaterials Research showcases high-quality, peer-reviewed research designed to address both practical and theoretical challenges in biomaterials science. As an open access journal, it promotes wider dissemination and accessibility of research findings, crucial for fostering innovation and collaboration within the scientific community. Researchers, professionals, and students alike are encouraged to contribute, read, and engage with the latest developments in this dynamic field.

Acta Biomaterialia, published by Elsevier Science Ltd, is a leading journal in the fields of biochemistry, biomaterials, biomedical engineering, biotechnology, and molecular biology. With an ISSN of 1742-7061 and an E-ISSN of 1878-7568, this prestigious journal has secured a remarkable position in the academic community, evidenced by its inclusion in the Q1 category across multiple disciplines for 2023. It ranks impressively at #21 in biochemistry, #16 in biomedical engineering, #18 in biotechnology, and #11 in biomaterials, reflecting its high impact and relevance to ongoing research and development. The journal provides a platform for disseminating innovative research and advancements in the design and application of biomaterials, contributing to scientific discussions that propel the field forward. Although it does not currently offer open access options, Acta Biomaterialia continues to attract contributions that advance our understanding of biomaterials and their interactions with biological systems, ensuring that researchers, professionals, and students remain informed about the latest trends and breakthroughs in this rapidly evolving area of study.

Materials Science & Engineering C-Materials for Biological Applications is a premier journal published by ELSEVIER, dedicated to advancing the field of biomaterials through interdisciplinary research. With a robust ISSN of 0928-4931, this journal has made its mark in the realms of Chemical Engineering and Materials Science, achieving impressive Scopus rankings within its categories, namely Rank #16/151 in Bioengineering (89th percentile) and Rank #13/112 in Biomaterials (88th percentile). Although the journal's coverage in Scopus has been discontinued since 2021, it remains a critical resource for researchers, professionals, and students eager to explore innovative materials and their applications in biological contexts. The journal’s open access policy enhances its accessibility, fostering a global exchange of knowledge and inspiring future advancements in the field of materials science.

Frontiers in Bioengineering and Biotechnology, published by FRONTIERS MEDIA SA in Switzerland, stands as a leading platform for innovative research and developments in the fields of bioengineering and biotechnology. Since its inception in 2013, this Open Access journal has garnered significant recognition, reflected in its impressive category rankings: Q1 in Biomedical Engineering and Q2 in Bioengineering, Biotechnology, and Histology for 2023. With a focus on fostering collaboration and knowledge sharing, it aims to provide researchers, professionals, and students with access to pioneering studies that push the boundaries of science and technology. The journal, which is indexed in prominent databases, boasts high visibility and impact, evidenced by its impressive rankings across various categories in Scopus. As it continues to converge from 2013 to 2024, Frontiers in Bioengineering and Biotechnology is dedicated to shaping the discourse in its field and promoting advancements that have the potential to transform healthcare and environmental sustainability.

Nanotechnology and Precision Engineering is a leading open access journal published by AIP Publishing, dedicated to advancing the fields of nanotechnology and precision engineering. Established in 2006, the journal has become a vital resource for researchers, professionals, and students, reflecting the latest advancements in Electrical and Electronic Engineering, Industrial and Manufacturing Engineering, Instrumentation, Mechanical Engineering, and Nanoscience. With an impressive variety of quartile rankings in Scopus—notably Q1 in several key engineering domains—the journal provides a robust platform for disseminating groundbreaking research. Noteworthy aspects include its open access format introduced in 2018, ensuring that high-quality research is freely accessible to a global audience. By maintaining a commitment to excellence and collaboration, Nanotechnology and Precision Engineering plays a crucial role in shaping the future of technology and innovation.

Progress in Biomedical Engineering, published by IOP Publishing Ltd, is a premier open-access journal that serves as a vital platform for the dissemination of innovative research in the field of biomedical engineering. With an impressive Q1 classification in the Biomedical Engineering category for 2023, this journal has established itself as a significant contributor to the advancement of engineering solutions that improve healthcare outcomes. Recognized for its high-quality and impactful publications, it ranks 51st out of 303 in its field on Scopus, placing it in the 83rd percentile. The journal aims to foster interdisciplinary collaboration and introduce pioneering methodologies and technologies that bridge the gap between engineering and medicine. By providing a pathway for rapid communication of fundamental and applied research, Progress in Biomedical Engineering is dedicated to shaping the future of healthcare technology. Access to its content ensures that researchers, professionals, and students remain at the forefront of biomedical innovation.

APL Bioengineering is a premier open-access journal published by AIP Publishing, dedicated to advancing the field of bioengineering and its interdisciplinary applications. Established in 2017, this journal serves as a vital platform for researchers, professionals, and students interested in the critical intersections of bioengineering, biomaterials, biomedical engineering, and biophysics. With an impressive impact factor and consistent rankings in the Q1 category across multiple domains, including biochemistry and materials science, APL Bioengineering has positioned itself among the top journals in its field. The journal aims to publish innovative original research, comprehensive reviews, and insightful case studies that further the understanding and application of bioengineering principles. Since its inception, APL Bioengineering has fostered a community of thought leaders, providing open access to ensure broad dissemination of knowledge and advancements that underpin the future of biomedical innovation.